Richard Vandivier
Concepts (442)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 21 | 2025 | 920 | 3.160 |
Why?
| | Apoptosis | 23 | 2014 | 2430 | 2.100 |
Why?
| | Phagocytosis | 15 | 2014 | 299 | 1.920 |
Why?
| | Macrophages, Alveolar | 14 | 2019 | 368 | 1.150 |
Why?
| | Tobacco Smoke Pollution | 3 | 2022 | 233 | 1.100 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 244 | 0.990 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 244 | 0.950 |
Why?
| | Respiratory Insufficiency | 4 | 2024 | 326 | 0.850 |
Why?
| | Smoking | 5 | 2018 | 1472 | 0.700 |
Why?
| | Lung | 13 | 2025 | 4109 | 0.690 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 478 | 0.680 |
Why?
| | Cigarette Smoking | 2 | 2025 | 99 | 0.660 |
Why?
| | rhoA GTP-Binding Protein | 6 | 2014 | 76 | 0.620 |
Why?
| | Pulmonary Ventilation | 2 | 2018 | 83 | 0.590 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 383 | 0.540 |
Why?
| | Pneumonia | 6 | 2023 | 631 | 0.520 |
Why?
| | Intensive Care Units | 7 | 2025 | 916 | 0.510 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2011 | 299 | 0.500 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 291 | 0.470 |
Why?
| | rac1 GTP-Binding Protein | 3 | 2012 | 56 | 0.430 |
Why?
| | Pulmonary Alveoli | 4 | 2016 | 383 | 0.430 |
Why?
| | Stem Cells | 2 | 2018 | 626 | 0.420 |
Why?
| | Methylprednisolone | 1 | 2014 | 64 | 0.410 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 62 | 0.410 |
Why?
| | Asthma | 3 | 2022 | 1767 | 0.400 |
Why?
| | Critical Illness | 8 | 2020 | 891 | 0.390 |
Why?
| | Patient Admission | 2 | 2025 | 218 | 0.390 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 5 | 2016 | 29 | 0.390 |
Why?
| | Hospital Mortality | 6 | 2025 | 1030 | 0.380 |
Why?
| | Bronchiectasis | 2 | 2006 | 112 | 0.380 |
Why?
| | Hypnotics and Sedatives | 2 | 2025 | 216 | 0.370 |
Why?
| | Case Management | 1 | 2012 | 67 | 0.370 |
Why?
| | Alcoholism | 5 | 2023 | 817 | 0.370 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 557 | 0.360 |
Why?
| | Coronary Disease | 1 | 2015 | 383 | 0.360 |
Why?
| | Hospitalization | 6 | 2025 | 2433 | 0.360 |
Why?
| | Humans | 68 | 2025 | 144759 | 0.360 |
Why?
| | rho GTP-Binding Proteins | 2 | 2010 | 56 | 0.360 |
Why?
| | Serotonin | 1 | 2014 | 293 | 0.350 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 74 | 0.350 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 62 | 0.340 |
Why?
| | Cystic Fibrosis | 4 | 2006 | 1158 | 0.320 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 3 | 2008 | 29 | 0.310 |
Why?
| | Patient Education as Topic | 2 | 2012 | 780 | 0.310 |
Why?
| | Inflammation Mediators | 4 | 2016 | 509 | 0.300 |
Why?
| | Neutrophils | 7 | 2010 | 1134 | 0.280 |
Why?
| | Mice | 21 | 2017 | 18339 | 0.280 |
Why?
| | Male | 39 | 2025 | 72315 | 0.280 |
Why?
| | Jurkat Cells | 6 | 2012 | 114 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2009 | 271 | 0.280 |
Why?
| | Female | 37 | 2025 | 78271 | 0.270 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 3 | 2006 | 12 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2018 | 2027 | 0.260 |
Why?
| | Signal Transduction | 6 | 2014 | 5226 | 0.260 |
Why?
| | Cells, Cultured | 9 | 2016 | 4154 | 0.260 |
Why?
| | Middle Aged | 24 | 2025 | 35875 | 0.260 |
Why?
| | Benzodiazepines | 2 | 2025 | 167 | 0.250 |
Why?
| | Animals | 30 | 2017 | 38058 | 0.250 |
Why?
| | Acyl Coenzyme A | 1 | 2006 | 31 | 0.250 |
Why?
| | Intracellular Fluid | 1 | 2006 | 25 | 0.250 |
Why?
| | rho-Associated Kinases | 3 | 2014 | 83 | 0.240 |
Why?
| | Lovastatin | 1 | 2006 | 37 | 0.240 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 43 | 0.240 |
Why?
| | Collectins | 1 | 2006 | 6 | 0.240 |
Why?
| | Retrospective Studies | 14 | 2025 | 17066 | 0.240 |
Why?
| | Opsonin Proteins | 1 | 2006 | 19 | 0.240 |
Why?
| | Inflammation | 9 | 2016 | 2878 | 0.240 |
Why?
| | Substance-Related Disorders | 2 | 2025 | 1094 | 0.230 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 113 | 0.230 |
Why?
| | Self Care | 1 | 2009 | 389 | 0.230 |
Why?
| | Quality of Life | 3 | 2022 | 3185 | 0.230 |
Why?
| | Ethanol | 1 | 2010 | 627 | 0.230 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 370 | 0.230 |
Why?
| | Leukocyte Elastase | 2 | 2002 | 75 | 0.220 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 51 | 0.220 |
Why?
| | Mice, Knockout | 8 | 2014 | 3121 | 0.220 |
Why?
| | Propofol | 1 | 2025 | 85 | 0.220 |
Why?
| | Shock, Septic | 2 | 2022 | 216 | 0.210 |
Why?
| | Oligopeptides | 1 | 2006 | 269 | 0.210 |
Why?
| | Influenza A virus | 1 | 2025 | 113 | 0.210 |
Why?
| | Mice, Inbred C57BL | 11 | 2014 | 5992 | 0.210 |
Why?
| | Cohort Studies | 6 | 2022 | 5960 | 0.200 |
Why?
| | Complement C1q | 2 | 2006 | 33 | 0.200 |
Why?
| | Aged | 17 | 2025 | 25913 | 0.200 |
Why?
| | Ibuprofen | 4 | 2001 | 84 | 0.200 |
Why?
| | Disease Progression | 4 | 2020 | 2847 | 0.200 |
Why?
| | Erythropoietin | 1 | 2004 | 100 | 0.200 |
Why?
| | Respiratory System | 2 | 2018 | 149 | 0.200 |
Why?
| | Lipopolysaccharides | 5 | 2016 | 863 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2025 | 459 | 0.190 |
Why?
| | Calreticulin | 1 | 2002 | 22 | 0.190 |
Why?
| | Adult | 22 | 2025 | 40449 | 0.180 |
Why?
| | Extracellular Matrix | 1 | 2006 | 553 | 0.170 |
Why?
| | Patient Discharge | 2 | 2018 | 983 | 0.170 |
Why?
| | Smoke-Free Policy | 1 | 2021 | 13 | 0.170 |
Why?
| | Transforming Growth Factor beta | 4 | 2013 | 479 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2022 | 11679 | 0.160 |
Why?
| | Smokers | 2 | 2019 | 137 | 0.160 |
Why?
| | Macrophages | 5 | 2010 | 1511 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2009 | 1217 | 0.160 |
Why?
| | Mice, Inbred ICR | 3 | 2013 | 113 | 0.160 |
Why?
| | Endotoxins | 5 | 2013 | 221 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 377 | 0.150 |
Why?
| | Autoimmune Diseases | 2 | 2014 | 463 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1143 | 0.150 |
Why?
| | Granulomatous Disease, Chronic | 2 | 2010 | 48 | 0.150 |
Why?
| | Nitroprusside | 1 | 1999 | 72 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 16 | 0.150 |
Why?
| | Influenza, Human | 1 | 2025 | 616 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 36 | 0.140 |
Why?
| | Macrolides | 1 | 2019 | 69 | 0.140 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 22 | 0.140 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 7 | 0.140 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.140 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 24 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 26 | 0.140 |
Why?
| | Bronchoalveolar Lavage Fluid | 5 | 2016 | 636 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 27 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2018 | 136 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 47 | 0.140 |
Why?
| | Time | 1 | 2018 | 86 | 0.140 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 320 | 0.130 |
Why?
| | Counseling | 1 | 2021 | 408 | 0.130 |
Why?
| | Polyneuropathies | 1 | 2017 | 57 | 0.130 |
Why?
| | Up-Regulation | 2 | 2019 | 851 | 0.130 |
Why?
| | Occupational Therapy | 1 | 2019 | 111 | 0.130 |
Why?
| | Epithelium | 1 | 2018 | 314 | 0.130 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 187 | 0.130 |
Why?
| | Nitric Oxide | 3 | 2006 | 897 | 0.130 |
Why?
| | Aged, 80 and over | 7 | 2022 | 8265 | 0.120 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1980 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2017 | 4557 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 769 | 0.120 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 541 | 0.120 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1907 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 219 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1356 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2021 | 588 | 0.120 |
Why?
| | Propensity Score | 2 | 2017 | 367 | 0.120 |
Why?
| | Receptors, IgG | 2 | 2009 | 76 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 342 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 175 | 0.120 |
Why?
| | Critical Care | 2 | 2020 | 695 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 332 | 0.120 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1519 | 0.110 |
Why?
| | Length of Stay | 3 | 2019 | 1337 | 0.110 |
Why?
| | Respiratory Mucosa | 2 | 2009 | 322 | 0.110 |
Why?
| | Emphysema | 3 | 2012 | 100 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 600 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1075 | 0.110 |
Why?
| | CD36 Antigens | 2 | 2006 | 32 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 324 | 0.100 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2608 | 0.100 |
Why?
| | Hyaluronan Receptors | 2 | 2006 | 102 | 0.100 |
Why?
| | United States | 8 | 2025 | 15966 | 0.100 |
Why?
| | Schistosomiasis mansoni | 1 | 2013 | 25 | 0.100 |
Why?
| | Schistosoma mansoni | 1 | 2013 | 41 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 66 | 0.100 |
Why?
| | Anticoagulants | 1 | 2018 | 722 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 341 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 573 | 0.100 |
Why?
| | Epithelial Cells | 3 | 2025 | 1125 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 248 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 311 | 0.090 |
Why?
| | Biological Transport | 1 | 2014 | 417 | 0.090 |
Why?
| | Echocardiography | 1 | 2016 | 652 | 0.090 |
Why?
| | Interleukin-6 | 3 | 2013 | 780 | 0.090 |
Why?
| | Respiration, Artificial | 3 | 2025 | 708 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 885 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2013 | 2182 | 0.090 |
Why?
| | Cell Line | 4 | 2012 | 2882 | 0.090 |
Why?
| | Acute Disease | 1 | 2015 | 1030 | 0.090 |
Why?
| | Phosphatidylserines | 2 | 2008 | 60 | 0.090 |
Why?
| | Doxycycline | 1 | 2012 | 62 | 0.090 |
Why?
| | Acetylcysteine | 2 | 2016 | 139 | 0.090 |
Why?
| | Colitis | 1 | 2014 | 280 | 0.080 |
Why?
| | Bronchoalveolar Lavage | 3 | 2017 | 89 | 0.080 |
Why?
| | Pyrroles | 1 | 2012 | 217 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2015 | 535 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 474 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1539 | 0.080 |
Why?
| | Membrane Glycoproteins | 3 | 2010 | 496 | 0.080 |
Why?
| | Erythrocytes | 2 | 2009 | 757 | 0.080 |
Why?
| | Rural Health Services | 1 | 2011 | 141 | 0.080 |
Why?
| | In Vitro Techniques | 2 | 2002 | 1047 | 0.080 |
Why?
| | Adolescent | 5 | 2022 | 22428 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2011 | 539 | 0.080 |
Why?
| | Peritonitis | 1 | 2010 | 84 | 0.080 |
Why?
| | Ceramides | 1 | 2010 | 116 | 0.080 |
Why?
| | Sepsis | 3 | 2020 | 640 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2925 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2006 | 1166 | 0.080 |
Why?
| | Amides | 1 | 2010 | 101 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2013 | 303 | 0.080 |
Why?
| | Stress Fibers | 1 | 2009 | 18 | 0.080 |
Why?
| | Amiloride | 1 | 2009 | 25 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2010 | 138 | 0.080 |
Why?
| | Endotoxemia | 2 | 2001 | 87 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1732 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 781 | 0.070 |
Why?
| | Alcohol-Related Disorders | 1 | 2010 | 120 | 0.070 |
Why?
| | PPAR gamma | 1 | 2010 | 176 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2011 | 724 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 779 | 0.070 |
Why?
| | Prevalence | 2 | 2025 | 2834 | 0.070 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 77 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 427 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 206 | 0.070 |
Why?
| | Telephone | 1 | 2009 | 175 | 0.070 |
Why?
| | Indoles | 1 | 2012 | 501 | 0.070 |
Why?
| | Gene Expression | 2 | 2010 | 1490 | 0.070 |
Why?
| | Risk Factors | 4 | 2018 | 10779 | 0.070 |
Why?
| | Actins | 1 | 2009 | 425 | 0.060 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 206 | 0.060 |
Why?
| | Blotting, Western | 1 | 2009 | 1187 | 0.060 |
Why?
| | Free Radical Scavengers | 1 | 2006 | 82 | 0.060 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2006 | 13 | 0.060 |
Why?
| | Protein Prenylation | 1 | 2006 | 19 | 0.060 |
Why?
| | Heart Rate | 3 | 2005 | 855 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5868 | 0.060 |
Why?
| | Models, Biological | 1 | 2014 | 1821 | 0.060 |
Why?
| | Down-Regulation | 2 | 2025 | 627 | 0.060 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 20 | 0.060 |
Why?
| | Pyridines | 1 | 2010 | 605 | 0.060 |
Why?
| | Lysophospholipids | 1 | 2006 | 77 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2006 | 118 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 173 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2006 | 105 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1496 | 0.060 |
Why?
| | Protein Biosynthesis | 1 | 2008 | 458 | 0.060 |
Why?
| | omega-N-Methylarginine | 1 | 2005 | 29 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2006 | 125 | 0.060 |
Why?
| | Health Care Costs | 1 | 2009 | 427 | 0.060 |
Why?
| | Arginine | 1 | 2006 | 262 | 0.060 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 56 | 0.050 |
Why?
| | Bronchi | 1 | 2006 | 267 | 0.050 |
Why?
| | Regeneration | 1 | 2006 | 197 | 0.050 |
Why?
| | Antigens, CD | 2 | 2006 | 555 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 310 | 0.050 |
Why?
| | Patient Satisfaction | 1 | 2009 | 704 | 0.050 |
Why?
| | Single-Blind Method | 3 | 2001 | 312 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2947 | 0.050 |
Why?
| | Blood Pressure | 3 | 2016 | 1769 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 456 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 538 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3154 | 0.050 |
Why?
| | Nitrates | 2 | 2005 | 100 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 105 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2875 | 0.050 |
Why?
| | Lung Diseases | 2 | 2009 | 787 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1486 | 0.050 |
Why?
| | Fibroblasts | 1 | 2008 | 1034 | 0.050 |
Why?
| | Complement Activation | 1 | 2006 | 411 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2194 | 0.050 |
Why?
| | Patient Readmission | 2 | 2019 | 758 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 9 | 0.050 |
Why?
| | Cathepsin G | 1 | 2002 | 4 | 0.050 |
Why?
| | Proteolipids | 1 | 2002 | 28 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 439 | 0.050 |
Why?
| | Cathepsins | 1 | 2002 | 24 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2009 | 1339 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2002 | 224 | 0.050 |
Why?
| | Fever | 3 | 2001 | 311 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | Immunotherapy | 1 | 2006 | 653 | 0.040 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 74 | 0.040 |
Why?
| | Heart Diseases | 1 | 2005 | 349 | 0.040 |
Why?
| | Colorado | 1 | 2011 | 4564 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 209 | 0.040 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2002 | 64 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 144 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 196 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 102 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 128 | 0.040 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
| | Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
| | Carbon Dioxide | 2 | 2001 | 242 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3540 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1370 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2001 | 338 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2008 | 2050 | 0.040 |
Why?
| | Cell Communication | 1 | 2002 | 324 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 650 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2016 | 367 | 0.040 |
Why?
| | Sputum | 1 | 2002 | 308 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1813 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.040 |
Why?
| | Glycoproteins | 1 | 2002 | 355 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 14105 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2010 | 35 | 0.040 |
Why?
| | Autoimmunity | 1 | 2006 | 926 | 0.040 |
Why?
| | Dyspnea | 1 | 2001 | 251 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 1999 | 601 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1999 | 92 | 0.040 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 11 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2010 | 124 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3604 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1253 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2003 | 965 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1999 | 423 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2018 | 51 | 0.030 |
Why?
| | Hospital Charges | 1 | 2017 | 46 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1720 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 144 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 170 | 0.030 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 103 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7173 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2019 | 433 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2018 | 205 | 0.030 |
Why?
| | Cytokines | 3 | 2013 | 2061 | 0.030 |
Why?
| | Protein Binding | 1 | 2002 | 2273 | 0.030 |
Why?
| | Teichoic Acids | 1 | 2016 | 18 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4271 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6048 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 213 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1658 | 0.030 |
Why?
| | Systole | 1 | 2016 | 178 | 0.030 |
Why?
| | Acute Kidney Injury | 2 | 2014 | 865 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 134 | 0.030 |
Why?
| | Risk | 1 | 2018 | 911 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2002 | 660 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2009 | 41 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 558 | 0.030 |
Why?
| | Cell Membrane | 2 | 2010 | 706 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2016 | 126 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1741 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1994 | 19 | 0.030 |
Why?
| | Dogs | 2 | 2006 | 437 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 574 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 824 | 0.030 |
Why?
| | Immunologic Factors | 1 | 1996 | 255 | 0.030 |
Why?
| | Ipilimumab | 1 | 2014 | 39 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 614 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1173 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 675 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 276 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 108 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 86 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2013 | 53 | 0.020 |
Why?
| | Hemorrhage | 1 | 2018 | 809 | 0.020 |
Why?
| | Hypotension | 1 | 2014 | 126 | 0.020 |
Why?
| | Phylogeny | 1 | 2017 | 1016 | 0.020 |
Why?
| | Diarrhea | 1 | 2014 | 192 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2117 | 0.020 |
Why?
| | Transfection | 2 | 2006 | 940 | 0.020 |
Why?
| | Endothelial Cells | 2 | 2010 | 869 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 549 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2013 | 217 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 560 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2527 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2013 | 430 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 506 | 0.020 |
Why?
| | Trachea | 1 | 2013 | 261 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 727 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3409 | 0.020 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.020 |
Why?
| | Zymosan | 1 | 2010 | 39 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1306 | 0.020 |
Why?
| | Nitric Oxide Synthase | 2 | 2005 | 235 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 42 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 81 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 389 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2832 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.020 |
Why?
| | Rats | 2 | 2010 | 5597 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2008 | 156 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 124 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2008 | 193 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2010 | 275 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 295 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2009 | 309 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 761 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 851 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2006 | 13 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2006 | 53 | 0.020 |
Why?
| | Gene Targeting | 1 | 2006 | 82 | 0.020 |
Why?
| | Syk Kinase | 1 | 2006 | 22 | 0.010 |
Why?
| | Fetal Distress | 1 | 2006 | 14 | 0.010 |
Why?
| | Random Allocation | 1 | 2006 | 363 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 109 | 0.010 |
Why?
| | Immunity | 1 | 2006 | 139 | 0.010 |
Why?
| | Nitrites | 1 | 2005 | 89 | 0.010 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2006 | 106 | 0.010 |
Why?
| | Hyperoxia | 1 | 2006 | 99 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 476 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 321 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2006 | 210 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 1047 | 0.010 |
Why?
| | Child | 2 | 2021 | 22633 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 101 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1382 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1325 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2006 | 433 | 0.010 |
Why?
| | Homeostasis | 1 | 2006 | 640 | 0.010 |
Why?
| | Chimera | 1 | 2002 | 61 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1087 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 104 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1199 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 194 | 0.010 |
Why?
| | Stroke Volume | 1 | 2005 | 651 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 2029 | 0.010 |
Why?
| | Interleukin-1 | 2 | 1996 | 961 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2001 | 36 | 0.010 |
Why?
| | Cell Count | 1 | 2002 | 320 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 766 | 0.010 |
Why?
| | Blood Gas Analysis | 1 | 2001 | 83 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 824 | 0.010 |
Why?
| | Chemokines | 1 | 2002 | 218 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2002 | 178 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 494 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 294 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 253 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 2002 | 208 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 1021 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 31 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1716 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 1999 | 26 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1999 | 81 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 163 | 0.010 |
Why?
| | Shivering | 1 | 1996 | 5 | 0.010 |
Why?
| | Acute-Phase Reaction | 1 | 1996 | 37 | 0.010 |
Why?
| | Blood Cell Count | 1 | 1996 | 54 | 0.010 |
Why?
| | Toxemia | 1 | 1996 | 4 | 0.010 |
Why?
| | Lactoferrin | 1 | 1996 | 36 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 158 | 0.010 |
Why?
| | Solubility | 1 | 1996 | 242 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 253 | 0.010 |
Why?
| | Kinetics | 1 | 1999 | 1627 | 0.010 |
Why?
| | Calmodulin | 1 | 1994 | 70 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6429 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 227 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3162 | 0.010 |
Why?
| | Electrocardiography | 1 | 1996 | 662 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 699 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2637 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 1000 | 0.010 |
Why?
| | Hemodynamics | 1 | 1996 | 1121 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 784 | 0.010 |
Why?
| | Sulfonamides | 1 | 1994 | 580 | 0.000 |
Why?
| | Prospective Studies | 1 | 1996 | 7990 | 0.000 |
Why?
|
|
Vandivier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|